Microbix Exhibiting at MEDICA Trade Fair

Showcasing Antigen and Quality Assessment Products

TORONTO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix^®), an innovator of biological products and technologies, announces that it will be exhibiting its antigens and quality assessment products at MEDICA, a leading international trade fair for the medical sector.

The 2018 MEDICA fair is being held at the Messe Dusseldorf exhibition grounds in Dusseldorf, Germany from November 12 to 15, 2018. At MEDICA, Microbix will showcase its industry-leading line of native antigen products and its new PROCEEDx™ brand quality assessment products (QAPs™).

Microbix’s line of purified and inactivated antigens is made from real viruses or bacteria and are thereby referred to as “native.” They are used for the development or manufacturing of medical tests to detect the level of patients’ antibodies to an infectious disease. Results of such tests provide clinically-important information concerning exposure to, or immunity against, the relevant pathogens. Microbix provides such critical antigens to more than 100 makers of such medical tests.

Microbix’s QAPs contain a precise quantity of stabilized antigen and have been engineered to closely resemble patient samples and thereby support quality assessment of each critical step of complex medical tests. Under the PROCEEDx brand, they are used for research, assay development, validation/verification of instruments, troubleshooting, and operator training. Currently, this product line comprises a wide range of respiratory and sexually transmitted infections (STIs), including its recently-launched human papilloma virus (HPV) line which is under evaluation by leading diagnostic companies. PROCEEDx products support both immunological and molecular assays (as necessary) and have extended stability in liquid form when stored at 2-8° Celsius.

Mr. Phil Casselli, SVP Sales and Business Development, is spearheading the Microbix team at MEDICA, accompanied by three colleagues across sales, product management and new product development. Phil noted the following about Microbix’s attendance at MEDICA, “The MEDICA fair provides us a convenient venue to catch-up with many of our existing customers, showcase new products such as PROCEEDx, and meet new potential customers and distributors for our QAPs lines.”

The Microbix team can be visited during MEDICA at Hall 3, Booth H14, as part of the Canadian Pavilion.

Microbix’s antigen and PROCEEDx products are available for sampling or purchase on its website at . Higher volume purchasers should contact Microbix’s representatives for a quotation.

About Microbix Biosystems

Microbix Biosystems Inc. specializes in the development of proprietary biological and technology solutions for human health and well-being. The Company manufactures a wide range of critical biological materials for the global diagnostics industry, notably antigens used in immunoassays or quality assessment and proficiency testing products. The Company also applies its biological expertise and technology platforms to create other innovative products and technologies. Currently it is working to commercialize two such proprietary products, (1) Kinlytic^® urokinase, a biologic thrombolytic drug used to treat blood clots and (2) LumiSort™ cell-sorting, a technology platform for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest, such as in sexing semen. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada.

Forward-Looking Information

This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, management’s discussion of products being introduced or exhibited, industry needs or trends, financial results or the outlook for the business, the risks associated with its financial results and stability, its biologicals business, development projects such as any referenced herein, operations in foreign jurisdictions, engineering and construction generally, production (including control over costs, quality, quantity and timeliness of delivery of products), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.

Please visit for recent Microbix filings.

For further information, please contact:

Company Contacts:

Cameron L. Groome, CEO

(905) 361-8910

Jim Currie, CFO

(905) 361-8910

Deborah Honig, Investor Relations – Adelaide Capital Markets

(647) 203-8793